| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3269480 | HPB | 2011 | 8 Pages |
Abstract
Epigenetic changes and profiles may correlate to the biological behaviour of tumours and clinical outcome of HCC patients. The use of DNA methylation profiles as a surrogate biomarker remains an active area of clinical cancer research.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Eric L. Sceusi, David S. Loose, Curtis J. Wray,